Results 121 to 130 of about 11,787 (237)

Développement de modèle PBPK pour l'optimisation de nanomédicaments

Embargo jusqu'au 12/11/2025Nanoparticles (NPs) are promising platforms for targeted drug delivery and improved diagnosis thanks to their unique physicochemical, biological and pharmacokinetic (PK) properties.
Ou, Jessica
core   +3 more sources

Human placental transfer of xenobiotics in health and disease: New approach methodologies for developmental and reproductive toxicology testing and mathematical modelling

The Journal of Physiology, EarlyView.
Abstract figure legend New approach methodologies (NAMs) to test the pharmaco‐ and chemicokinetics of compound transfer across the human placental barrier in late pregnancy. Abstract This review addresses an important and timely topic at the intersection of placental biology with respect to barrier transfer kinetics, toxicology and mathematical ...
Paul Brownbill, Eleanor Doman
wiley   +1 more source

Predicting Drug Transfer Into Human Milk With the Simcyp Simulator: A Contribution From the ConcePTION Project

CPT: Pharmacometrics & Systems Pharmacology
Physiologically‐based pharmacokinetic (PBPK) modeling can support decision‐making on maternal medication use during breastfeeding. This study aimed to enhance lactation PBPK models in two ways.
Julia Macente, Nina Nauwelaerts, Justine Marine Badée, Rodolfo Hernandes Bonan, Miao‐Chan Huang, Martje Van Neste, Anne Smits, Karel Allegaert, Hedvig Nordeng, Markus Hovd, Frederico Severino Martins, Pieter Annaert   +11 more
doaj   +1 more source

Toward Predictable Nanomedicine: Current Forecasting Frameworks for Nanoparticle–Biology Interactions

Advanced Intelligent Discovery, Volume 2, Issue 5, October 2026.
Predictive models successfully screen nanoparticles for toxicity and cellular uptake. Yet, complex biological dynamics and sparse, nonstandardized data limit their accuracy. The field urgently needs integrated artificial intelligence/machine learning, systems biology, and open‐access data protocols to bridge the gap between materials science and safe ...
Mariya L. Ivanova, Michael Nicholls, Nicola Russo, Gueorgui Mihaylov, Konstantin Nikolic   +4 more
wiley   +1 more source

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug–Drug Interactions for Orforglipron, a Small Molecule Glucagon‐Like Peptide‐1 Receptor Agonist

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 979-990, October 2026.
Orforglipron is an orally administered, small‐molecule glucagon‐like peptide‐1 receptor agonist in clinical development for the treatment of type 2 diabetes and obesity. Orforglipron is a substrate of CYP3A4, organic anion transporting polypeptides (OATPs) 1B/1B3, and P‐glycoprotein (P‐gp); however, precipitants commonly used to define these mechanisms
Bridget L. Morse, David E. Coutant, Xiaosu Ma, Sohini Raha, Keerthan Aithal, Clare Nicoll, Luc R. A. Rougée, Shobha Bhattachar   +7 more
wiley   +1 more source

Exploring Tafamidis Effects Through PBPK-QSP Modelling

Pharmaceutics
Background/Objectives: Tafamidis, a transthyretin kinetic stabilizer, increases circulating transthyretin levels in treated patients. While this effect is well documented, its underlying mechanism remains incompletely understood. This study aimed to evaluate the performance of a Physiologically Based Pharmacokinetic (PBPK) model performance and to ...
Seweryn Ulaszek, Bartek Lisowski, Barbara Wiśniowska, Sebastian Polak   +3 more
openaire   +4 more sources

Development, Early Verification and Application of a North American Pediatric PBPK Model, Comparison With the North European Pediatric Population

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Physiologically based pharmacokinetic (PBPK) models are increasingly used in pediatric drug development and matching such models to the target population is an important consideration. A US pediatric PBPK model was developed incorporating four sub‐groups describing physiology and enzymatic/transporter levels for White, African American ...
Trevor N. Johnson, Fiskani Kondowe, Joyce van der Heijden, Saskia N. de Wildt, Iain Gardner, Karen Rowland Yeo   +5 more
wiley   +1 more source

Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach

Frontiers in Pharmacology
Purpose: This study aimed to develop and validate a physiologically based pharmacokinetic (PBPK) model for osimertinib (OSI) to predict plasma trough concentration (Ctrough) and pulmonary EGFRm+ (T790M and L858R mutants) inhibition in Caucasian, Japanese,
Feng Liang, Yimei Zhang, Qian Xue, Na Yao   +3 more
doaj   +1 more source

PBPK-modell av oxikodon

Bakgrund: Oxikodon syntetiserades år 1916 och togs i klinisk användning ett år senare. Eftersom den aktiva läkemedelsingrediensen utvecklades för så länge sedan, genomgick den inte samma godkännandeprocess som behövs idag.
Kosunen-Koskivaara, Suvi
core   +1 more source

Model Master File Framework: A Regulatory Path Advancing Modeling and Simulation Applications

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT To advance drug product development, regulatory decision making, and improve patient care, FDA has committed to the quantitative medicine paradigm that involves, among others, quantitative in silico methodologies and tools developed based on nonclinical, clinical, and real‐world sources. In this Perspective, Model Master File (MMF) submissions
Eleftheria Tsakalozou, Rachel Erdman, Lei Zhang, Robert Lionberger, Lanyan Fang   +4 more
wiley   +1 more source